Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19
Status:
Completed
Trial end date:
2021-04-16
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy of oral favipiravir plus standard of
care treatment (SOC) compared with placebo plus SOC in reducing the duration of shedding of
SARS-CoV2 virus in patients with mild or asymptomatic COVID-19.